Connect with us

Cancer

Juncker Plan supports cancer research with €40 million loan to #Indivumed

SHARE:

Published

on

We use your sign-up to provide content in ways you've consented to and to improve our understanding of you. You can unsubscribe at any time.

The European Investment Bank (EIB) is providing a loan of €40 million to Indivumed GmbH, a physician-led, global oncology company with headquarters in Germany. The new funding will allow Indivumed to continue its development of a global database, supporting the work of cancer researchers by providing access to data from cancer patients, as well as investing in the latest technology to better understand complex cancer data.

The financing for this project is guaranteed by the European Fund for Strategic Investments (EFSI), the central pillar of the Investment Plan for Europe. Health and Food Safety Commissioner Vytenis Andriukaitis (pictured) said: "The health-care systems in many member states have growing needs for investments in modern infrastructure, innovative technologies and new models of care. The investment in Indivumed shows that the EU Institutions are committed to assist Member States in doing just that. I am pleased that the EIB is signing this agreement today to help stakeholders in the health sector make more use of the Investment Plan for Europe for the benefit of our citizens."

For more information and the latest Investment Plan results see the Investment Plan website

Share this article:

Share this:
EU Reporter publishes articles from a variety of outside sources which express a wide range of viewpoints. The positions taken in these articles are not necessarily those of EU Reporter. Please see EU Reporter’s full Terms and Conditions of publication for more information EU Reporter embraces artificial intelligence as a tool to enhance journalistic quality, efficiency, and accessibility, while maintaining strict human editorial oversight, ethical standards, and transparency in all AI-assisted content. Please see EU Reporter’s full A.I. Policy for more information.

Trending